PEDIATRICS Vol. 102 No. 2 Supplement August 1998, pp. 486-488
Optimizing Estrogen Replacement Treatment in Turner Syndrome
Received Feb 6, 1998; accepted Mar 20, 1998.
,
, and
From the * Department of Pediatrics, University of Chicago,
Chicago, Illinois; Department of Pediatrics, Nemours Children's
Clinic, Jacksonville, Florida; § Division of Endocrinology, University
of Pennsylvania, Philadelphia, Pennsylvania; Department of
Pediatrics, University of South Florida, Tampa, Florida; and
# Department of Medical Affairs, Genentech Inc, South San Francisco,
California.
Estrogen has a biphasic effect on growth, stimulatory at low doses but inhibitory at higher doses. Therefore, designing optimal sex hormone replacement treatment in girls with Turner syndrome (TS) who are being treated with growth hormone (GH) involves considering the dose and form of the estrogen as well as the route and timing of its administration. We report here a preliminary analysis of a study to test the concept that an optimal estrogen replacement regimen should consist of estradiol administered in a low dose by a systemic route.
The study population consisted of 9 girls with TS who had been treated with GH for 6 or more months. When the girls were 12 to 15 years old, we added depot estradiol at a monthly intramuscular dose of 0.2 mg and increased the dose at 6-month intervals to 0.4, 0.6, and, in 7 of the girls, 0.8 mg. We compared the results in these subjects with those in a matched group of 37 patients with TS in whom routine estrogen treatment had been started at similar ages and who were treated with a similar course of GH therapy.
The gain in height at 2 years was 2.6 cm greater in those who were treated with depot estradiol than in those who were treated with routine estrogen. The bone age in the patients who were treated with depot estradiol increased in proportion to their chronologic age, suggesting that this difference indicates an increase in their predicted adult height. We conclude that using very low doses of systemic estradiol to induce puberty before the age of 15 years in girls with TS who are treated with GH, instead of using routine estrogen therapy, can result in increased final heights.
Key words: Turner syndrome, estrogen replacement, growth hormone, estradiol.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. M. Nabhan, L. A. DiMeglio, R. Qi, S. M. Perkins, and E. A. Eugster Conjugated Oral versus Transdermal Estrogen Replacement in Girls with Turner Syndrome: A Pilot Comparative Study J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2009 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Rosenfield, N. Devine, J. J. Hunold, N. Mauras, T. Moshang Jr., and A. W. Root Salutary Effects of Combining Early Very Low-Dose Systemic Estradiol with Growth Hormone Therapy in Girls with Turner Syndrome J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6424 - 6430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Piippo, H. Lenko, P. Kainulainen, and I. Sipila Use of Percutaneous Estrogen Gel for Induction of Puberty in Girls with Turner Syndrome J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3241 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.I. Tazuke and A.A. Milki Endometrioma of uterine serosa in a woman with mosaic Turner's syndrome receiving hormone replacement therapy: Case report Hum. Reprod., November 1, 2002; 17(11): 2977 - 2980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Quigley, B. J. Crowe, D. G. Anglin, and J. J. Chipman Growth Hormone and Low Dose Estrogen in Turner Syndrome: Results of a United States Multi-Center Trial to Near-Final Height J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2033 - 2041. [Abstract] [Full Text] [PDF]
|
|
